Fluorouracil Treatment Via Colon for Colorectal Cancer - Trial NCT06385418
Access comprehensive clinical trial information for NCT06385418 through Pure Global AI's free database. This Phase 2 trial is sponsored by The Second Hospital of Nanjing Medical University and is currently Recruiting. The study focuses on Colorectal Cancer. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Colonic local administration of fluorouracil with enhanced adhesion
Interventional
drug
Sponsor & Location
The Second Hospital of Nanjing Medical University
Timeline & Enrollment
Phase 2
May 01, 2024
May 01, 2029
Primary Outcome
Objective response rate (according to RECIST1.1, investigator assessment)
Summary
Fluorouracil (5-FU) is a commonly used drug for colorectal cancer (CRC). Thermosensitive
 hydrogel presents a promising carrier for 5-FU to address challenges encountered with
 traditional administration methods. We propose an integrated approach utilizing colonic
 transendoscopic enteral tubing to cover the entire colon flexibly, coupled with a
 thermo-sensitive gel to enhance the adhesion of 5-FU. This clinical trial aims to assess the
 feasibility, safety, and efficacy of this approach for treating CRC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06385418
Non-Device Trial